Table 2

Progression-free survival

VariableNProgression (n)5-year PFS rate (95% CI)HR (95% CI)*P value*†
Age at diagnosis
 <50 years681183.7% (71.6% to 91%)10.214
>50 years1142678.3% (68.7% to 85.2%)1.56 (0.77 to 3.17)
Race
 White1312780.4% (71.8% to 86.6%)10.986
 Non-white34683.2% (63.5% to 92.8%)0.99 (0.41 to 2.42)
Stage (FIGO)
 IA81790.7% (81.3% to 95.5%)1 <0.001
 IC139683% (65.9% to 92%)1.87 (0.63 to 5.57)
 IC216567.7% (31% to 87.8%)4.21 (1.34 to 13.30)
 IC3251255.2% (29.7% to 74.7%)7.16 (2.81 to 18.23)
 IIA9453.3% (17.7% to 79.6%)6.7 (1.96 to 22.94)
 IIB12383.3% (48.2% to 95.6%)3.5 (0.90 to 13.55)
Risk category
 Low risk (IA/IC1)1201388.2% (80.5% to 93%)1 <0.001
 High risk (IC2/IC3/IIA/IIB)622463.8% (48.2% to 75.8%)4.37 (2.22 to 8.60)
Concordant endometriosis
 Absent601080.9% (67% to 89.4%)10.257
 Present1222780.2% (71.3% to 86.5%)1.52 (0.73 to 3.14)
p53 IHC
 Aberrant33Not reached1 <0.001
 Wild-type631384.2% (71.6% to 91.5%)0.06 (0.02 to 0.25)
MMR IHC
 Retained761878.8% (66.5% to 87%)10.815
 Deficient6183.3% (27.3% to 97.5%)0.75 (0.10 to 5.68)
Post-operative chemotherapy‡
 None15292.9% (59.1% to 99%)10.687
 Received1653479.8% (72.2% to 85.5%)1.40 (0.34 to 5.86)
Platinum cycles‡
 015292.9% (59.1% to 99%)
 1–3190100%
 >31463477.4% (69.2% to 83.7%)
  • *If a variable contains certain levels event=0, then there is no HR or p value provided.

  • †P value obtained by applying permutation log-rank test with 5000 permutation times if events count n <3.

  • ‡‘Post-operative chemotherapy’ and ‘Platinum cycles’ related variables are analyzed using landmark analysis with landmark time set to be 4 months.

  • FIGO, Federation of Gynecology and Obstetrics; IHC, immunohistochemistry; MMR, mismatch repair; PFS, progression-free survival.